New combo therapy tested for tough blood cancer cases
NCT ID NCT05393674
Summary
This study is testing whether combining two drugs, fedratinib and nivolumab, can help control myelofibrosis, a serious bone marrow cancer, in patients whose disease did not respond well to standard JAK-inhibitor therapy. It will involve about 30 adults with primary or secondary myelofibrosis who still have significant symptoms or disease markers. The main goal is to see if this new combination can shrink the spleen, improve blood counts, reduce symptoms, and help patients live longer without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johannes Wesling Klinikum
Minden, Germany
-
Medizinische Hochschule
Hanover, Germany
-
Uniklinik Ulm
Ulm, Germany
-
University Medicine Greifswald
Greifswald, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
-
Universitätsklinikum Halle (Saale)
Halle, Germany
-
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Conditions
Explore the condition pages connected to this study.